Related Experiment Video
Updated: Mar 28, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
[Application of pre- and post-transfusion virological controls prior to the suppression of their recommendation]
H Petit1, S Laperche, J-J Lefrère
1Laboratoire d'hématologie, CHU d'Amiens, place Victor-Pauchet, 80054 Amiens, France.
In 1996, due to a residual risk of transfusion-transmitted virus, a circular of the French Health Authorities (DGS/DH n degrees 96-609) recommended proposing to recipients of cellular blood products a test for antibodies to human immunodeficiency virus (HIV) and for antibodies to hepatitis C virus, before and three months after transfusion. We have evaluated the application of this recommendation throughout the whole transfused population of a French Hospital over a three month period. In addition, this study allowed us to establish the vaccination status against hepatitis B virus (HBV) infection in this exposed population including transfusion and nosocomial risks. The results showed a failure in the application of the 1996 circular and confirmed the validity of the abrogation of this circular by a recent circular (11 January 2006) of the French health authorities. It also showed that only a minority of patients needing a vaccination against HBV were afforded such treatment during their hospitalization.
In 1996, due to a residual risk of transfusion-transmitted virus, a circular of the French Health Authorities (DGS/DH n degrees 96-609) recommended proposing to recipients of cellular blood products a test for antibodies to human immunodeficiency virus (HIV) and for antibodies to hepatitis C virus, before and three months after transfusion. We have evaluated the application of this recommendation throughout the whole transfused population of a French Hospital over a three month period. In addition, this study allowed us to establish the vaccination status against hepatitis B virus (HBV) infection in this exposed population including transfusion and nosocomial risks. The results showed a failure in the application of the 1996 circular and confirmed the validity of the abrogation of this circular by a recent circular (11 January 2006) of the French health authorities. It also showed that only a minority of patients needing a vaccination against HBV were afforded such treatment during their hospitalization.
More Related Videos
18:48In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 10, 2014